AbbVie Inc. (ABBV) stock analysis: Buy

Bro's Verdict
Deep Dive

Rating

BUY

Confidence

72%

Target Price

$315.00

Upside

+13.3%

Horizon

medium

AbbVie trades at 19.9x NTM P/E (17.5x on the latest revision snapshot), roughly 44% below its two-year average forward multiple, despite a 40% operating margin and +17.2% NTM EPS growth driven by the Skyrizi/Rinvoq ramp. The analyst's $315 target applies ~19.2x to FY+2 EPS of $16.39, still below historical averages, and sits above the consensus $292.21/median $300. Binary pipeline risk and IRA pricing cap the re-rating, warranting moderate confidence.

Executive Summary

•Skyrizi and Rinvoq are now the earnings engine, more than offsetting Humira erosion and driving NTM revenue of $67.61b (+8.7%) and NTM EPS growth of +17.2%.

•Forward earnings multiples are undemanding: 19.9x NTM P/E on $13.99 consensus EPS (17.5x on the $15.85 revision snapshot) sits 44% below the 2 year average of 31.3x, implying meaningful re rating potential if growth delivers.

•The revenue multiple tells the opposite story: 7.8x EV/Rev is +2.5 SD above the 2 year average of 5.0x, a direct function of the step change in operating margin to 40%, so earnings based frameworks are the correct lens here.

•Neuroscience (tavapadon, ABBV-295, emraclidine) and aesthetics recovery are the swing factors, but binary pipeline risk and IRA pricing on Imbruvica cap the near term multiple.

Financial Snapshot

•Revenue (TTM): $64.39b

•Revenue growth (NTM): +8.7% YoY

•Gross margin: 72.8%

•Operating margin: 40.0%

•Net margin: 9.8% (depressed by one time charges and acquired IPR&D)

•Forward EPS (NTM): $13.99

•Forward EPS growth: +17.2%

•FY+2 EPS estimate: $16.39

•FY+2 revenue estimate: $73.47b

•Quarterly revenue (last 4): $16.99b, $15.00b, $16.62b, $15.78b

•Quarterly net income (last 4): $3.61b, $0.69b, $1.82b, $0.19b (highly volatile on one time items)

•Quarterly EPS: Not disclosed

•Market cap: $561.14b

•Net debt: Not disclosed

Forward Outlook

•NTM revenue guided to $67.61b, implying +8.7% growth as Skyrizi and Rinvoq absorb the residual Humira decline

•FY+2 revenue estimate of $73.47b implies a mid single digit two year revenue CAGR from the NTM base

•NTM EPS of $13.99 (+17.2%) reflects operating leverage as one time charges roll off and immunology mix improves

•FY+2 EPS of $16.39 implies ~17% cumulative growth on the NTM base

•Operating margin expected to hold near 40%, with net margin normalising higher as acquired IPR&D and litigation charges fade

•IRA negotiated pricing on Imbruvica is a 2026 headwind; Skyrizi and Rinvoq are not yet selected but remain medium term exposure

•Consensus EPS revision trend is upward ($15.85 latest snapshot versus $13.99 FMP basis), a positive signal on estimate momentum

Valuation Analysis

•NTM P/E: 19.9x (on $13.99 consensus EPS)

•NTM P/E: 17.5x (on $15.85 revision snapshot)

•NTM P/S: 7.27x

•NTM EV/EBIT: 15.6x

•NTM EV/EBITDA: 13.4x

•TTM P/E: ~89x (distorted by depressed TTM net income; not meaningful)

•Own history, forward P/E: 17.5x vs 2 year average 31.3x (-44%, -0.5 SD)

•Own history, forward EV/EBITDA: 13.4x vs 2 year average 15.3x (-12%)

•Own history, forward EV/EBIT: 15.6x vs 2 year average 18.2x (-14%)

•Own history, forward EV/Rev: 7.8x vs 2 year average 5.0x (+57%, +2.5 SD)

•Implied price at historical average P/E: $496.88

•Implied price at historical average EV/EBITDA: $322.95

•Implied price at historical average EV/EBIT: $330.02

•Implied price at historical average EV/Rev: $163.46

•Sell side price target: consensus $292.21, median $300, range $235 to $320

•Ratings: 32 Buy / 11 Hold / 1 Sell (consensus Buy)

•BMY: ~12.4x TTM P/E, $115.2b market cap, deep value, patent cliff exposure

•JNJ: ~29.0x TTM P/E, $603.6b market cap, diversified medtech and pharma premium

•AMGN: ~25.9x TTM P/E, $225.8b market cap, obesity pipeline optionality

•LLY: ~39.5x TTM P/E, $1,048.5b market cap, GLP-1 growth leader, premium multiple

•ABBV screens mid range on earnings versus peers, cheap on growth adjusted basis given +17% NTM EPS growth (PEG ~1.2x)

Key Risks & Catalysts

Risks

•Humira erosion running ahead of Skyrizi and Rinvoq offset, pressuring the immunology top line

•IRA negotiated pricing on Imbruvica, with eventual selection risk for Skyrizi and Rinvoq

•Neuroscience pipeline binary risk, including prior emraclidine Phase 2 disappointment in schizophrenia

•Aesthetics demand remains soft, with Botox Cosmetic and Juvederm recovery uncertain

•Revenue multiple stretched at 7.8x EV/Rev versus 5.0x history, leaving little room for growth disappointment

•Biosimilar and competitive pressure across oncology and immunology

•Legacy Allergan litigation and contingent liabilities

•Insider selling: one open market sale of $8.18m (32,710 shares) by the Chief Business and Strategy Officer in the last 90 days, no open market buys

•Institutional 13F holders fell sharply QoQ, with 4,013 positions closed

Catalysts

•Q3 2026 earnings on 30 October 2026, key read on Skyrizi and Rinvoq momentum

•Continued Skyrizi and Rinvoq label expansion and share gains

•Tavapadon Parkinson's launch and commercial ramp

•ABBV-295 amylin analog Phase 1 obesity data, positive tolerability and PK profile presented at EASD 2026

•Emraclidine and broader Cerevel neuroscience readouts

•Aesthetics franchise demand recovery

•Venclexta plus acalabrutinib approval in first line CLL, expanding oncology

•Continued net debt reduction and capital allocation flexibility post Allergan

•Upward NTM EPS revisions ($15.85 latest versus $13.99 prior basis)

Investment Thesis

AbbVie is a high quality immunology compounder trading at a discount to its own history on the metrics that matter. The Skyrizi and Rinvoq ramp has decisively turned the narrative from Humira erosion to durable growth, with NTM revenue of $67.61b (+8.7%) and NTM EPS growth of +17.2%. At 19.9x NTM P/E (17.5x on the latest revision), the stock sits 44% below its 2 year average forward multiple, a gap that looks unjustified against a 40% operating margin and a mid teens EPS growth trajectory. The stretched 7.8x EV/Rev is a mechanical artefact of margin expansion, not a valuation warning, and should not override the earnings based case.

The swing factors are the pipeline and capital allocation. Tavapadon, ABBV-295 and the Cerevel assets offer genuine optionality, but the prior emraclidine Phase 2 miss is a reminder that neuroscience is binary. Aesthetics recovery is the nearer term lever, and continued debt reduction post Allergan supports both buybacks and bolt on M&A. The principal overhang is IRA pricing, with Imbruvica already selected and Skyrizi and Rinvoq eventual candidates, which caps how far the multiple can re rate.

I rate ABBV a Buy with a 12 month price target of $315, implying ~13% upside from $278.13. This applies roughly 19.2x to FY+2 EPS of $16.39, a modest premium to the current NTM multiple and still well below the historical average. The setup favours investors willing to underwrite execution on the immunology ramp and tolerate binary pipeline risk, with the consensus target of $292.21 and median of $300 offering a floor to the re rating case.

Written by Buy Side Bro's AI analyst from financials, consensus, filings and recent news. General information only, not financial advice.

AbbVie Inc. ABBV

Bro's Verdict
Deep Dive

Executive Summary

Financial Snapshot

Forward Outlook

Valuation Analysis

Key Risks & Catalysts

Investment Thesis

Run your own analysis free

Bro's VerdictDeep Dive

Executive Summary

Financial Snapshot

Forward Outlook

Valuation Analysis

Key Risks & Catalysts

Investment Thesis

Run your own analysis free

Bro's Verdict
Deep Dive